Compare CVS Health Corp (CVS) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? CVS Health Corp trades at $86.43 (market cap $112.49B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.79 (market cap $72.20B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays a 3.02% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Vanguard Intermediate Term Corporate Bond ETF for 61 Days on average.
| CVS | VCIT | |
|---|---|---|
Market Cap | $112.49B | $72.20B |
Volume | 8,467,392 | 14,162,206 |
Sector | Health | Fixed Income |
52-Week High | $110.60 | $84.82 |
52-Week Low | $70.08 | $77.98 |
Typical Hold Time | 83 Days | 61 Days |
Enterprise Value | $174.83B | — |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
VCIT trades at $78.27 with minimal daily movement (+0.04%). Technical indicators show a bearish trend with strong selling pressure in moving averages, though oscillators are neutral. The ETF offers a 4.8% yield with a 6-year duration, positioning it as a balanced income option among investment-grade corporate bond ETFs. Recent institutional buying includes Engineers Gate Manager LP's $1.27 million purchase in September 2026.
VCIT presents a compelling risk-return profile for income-focused investors seeking corporate bond exposure. The fund's low 0.03% expense ratio and higher yield compared to treasury alternatives provide value, though interest rate sensitivity and market volatility remain key risks. Analyst sentiment is generally positive given its competitive positioning in the fixed income ETF space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
